Ipraxa (Ipratropium Bromide Monohydrate)

Ipratropium bromide blocks muscarinic (M1, M2, M3) acetylcholine receptors on airway smooth muscle. By preventing acetylcholine‑induced bronchoconstriction, it promotes relaxation of the bronchial tubes, leading to widened airways and easier airflow without stimulating beta‑adrenergic receptors.

The specific dose and frequency of Ipraxa are determined by the prescribing healthcare professional based on the individual’s condition, severity, and response to therapy. Patients should follow the prescriber’s instructions and the product labeling for proper use.

Safety data for ipratropium bromide in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing Ipraxa to pregnant or nursing individuals.

To order Ipraxa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Ipraxa (ipratropium bromide) is an anticholinergic bronchodilator, whereas agents like albuterol are short‑acting beta‑agonists. Ipratropium provides longer‑lasting bronchodilation with fewer cardiac effects, but it may be less rapid in relieving acute bronchospasm. Often, it is used in combination with beta‑agonists for additive benefit.

Ipraxa should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing the product.

Ipraxa is delivered by inhalation, typically using a nebulizer or a metered‑dose inhaler as directed by a healthcare professional. The patient inhales the medication into the lungs, ensuring the device is cleaned and maintained according to the manufacturer’s instructions.

Serious adverse events, although rare, include paradoxical bronchospasm, angioedema, severe allergic reactions, urinary retention, and acute glaucoma. Patients should seek immediate medical attention if they experience swelling of the face or throat, difficulty breathing, or sudden worsening of respiratory symptoms.

Ipraxa should be avoided in individuals with known hypersensitivity to ipratropium bromide or any component of the formulation. Caution is advised for patients with narrow‑angle glaucoma, urinary retention, severe prostate enlargement, or significant renal impairment, and it should be used only under medical supervision in these cases.